The National Institutes of Health has awarded a $13 million grant over five years to develop and disseminate new stem cell-based technologies and assays for studying autism spectrum disorder (ASD) and other mental health diseases to a consortium of researchers at the University of California, San Diego and the Salk Institute for Biological Studies, working in tandem with leaders in the biotechnology sector.
In 2014, only 10 of the nation’s 132 pharmacy schools achieved a 100 percent pass rate on first-time attempts at the North American Pharmacist Licensure Examination (NAPLEX). The University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences was one of them, passing all 54 students who took the exam for the first time.
The theme for the University of California, San Diego’s 10th annual California Native American Day celebration is “Unsettled Stories: Reclaiming This Land,” and will include a kickoff event Sept. 25 as well as an undergraduate research symposium, a Native American film festival, spoken word performances, a powwow and more throughout the 2015-16 academic year.
Albert La Spada, MD, PhD, professor of pediatrics, cellular and molecular medicine and neurosciences at University of California, San Diego School of Medicine, has received a 2015 Harrington Scholar award to advance his work on a therapy for Spinocerebellar ataxia type 7 (SCA7), a rare but devastating neurological disorder that can lead to blindness and progressive loss of physical coordination.
Approximately 20 million Americans will experience some type of gastroesophageal reflux disease, or GERD, in their lives. In some cases, patients suffer resulting heart burn or acid regurgitation so severe that they require surgery to repair damage to their esophagus. A clinical trial at UC San Diego Health is using a new, FDA-approved device that reconstructs the esophagus through the mouth and requires no incisions.
More than five million Americans are living with Alzheimer’s disease (AD). Of them, 400,000 also have Down syndrome. Both groups have similar looking brains with higher levels of the protein beta amyloid. In fact, patients with Down syndrome develop the abnormal protein at twice the rate. Results of a pilot study confirms the pathogenic role of beta amyloid in dementia as seen in both AD and Down syndrome.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
